TY - JOUR
T1 - Correction
T2 - First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (Journal of Experimental & Clinical Cancer Research, (2023), 42, 1, (76), 10.1186/s13046-023-02649-6)
AU - Cole, Christopher B.
AU - Morelli, Maria Pia
AU - Fantini, Massimo
AU - Miettinen, Markku
AU - Fetsch, Patricia
AU - Peer, Cody
AU - Figg, William D.
AU - Yin, Tyler
AU - Houston, Nicole
AU - McCoy, Ann
AU - Lipkowitz, Stanley
AU - Zimmer, Alexandra
AU - Lee, Jung min
AU - Pavelova, Miroslava
AU - Villanueva, Erin N.
AU - Trewhitt, Kathryn
AU - Solarz, B. Brooke
AU - Fergusson, Maria
AU - Mavroukakis, Sharon A.
AU - Zaki, Anjum
AU - Tsang, Kwong Y.
AU - Arlen, Philip M.
AU - Annunziata, Christina M.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Following publication of the original article [1], an error was identified in Fig. 2, specifically: Fig. 2b - CL/F (mL/hr) needs to be corrected in CL/F (L/hr) Furthermore, two Supplementary Materials should also be uploaded. The added Supplementary Materials are: Additional file 7: Supplementary Materials and Methods. Additional file 8: NEO-201 protocol. This modification does not affect the integrity of the results. Clinical Pharmacokinetics of NEO-201 A. NEO-201 serum concentrations averaged for each dose level and plotted over time. B. Noncompartmental analysis of first dose of NEO-201 including the mean estimates for relevant PK parameters during dense PK sampling following the first dose given on C1D1. *Data presented as arithmetic means (%CV) due to low numbers in each group. 1 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 2 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 3 Four patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 4 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 5 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. C. Individual NEO-201 serum concentration–time profiles of 1.0 mg/kg cohort. D-E. Individual NEO-201 serum concentration–time profiles of patients in 1.5 mg/kg cohort (D) and 2.0 mg/kg cohort (E). F-G. Differences in NEO-201 distribution volume by sex (F) and body size (G).
AB - Following publication of the original article [1], an error was identified in Fig. 2, specifically: Fig. 2b - CL/F (mL/hr) needs to be corrected in CL/F (L/hr) Furthermore, two Supplementary Materials should also be uploaded. The added Supplementary Materials are: Additional file 7: Supplementary Materials and Methods. Additional file 8: NEO-201 protocol. This modification does not affect the integrity of the results. Clinical Pharmacokinetics of NEO-201 A. NEO-201 serum concentrations averaged for each dose level and plotted over time. B. Noncompartmental analysis of first dose of NEO-201 including the mean estimates for relevant PK parameters during dense PK sampling following the first dose given on C1D1. *Data presented as arithmetic means (%CV) due to low numbers in each group. 1 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 2 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 3 Four patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 4 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 5 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. C. Individual NEO-201 serum concentration–time profiles of 1.0 mg/kg cohort. D-E. Individual NEO-201 serum concentration–time profiles of patients in 1.5 mg/kg cohort (D) and 2.0 mg/kg cohort (E). F-G. Differences in NEO-201 distribution volume by sex (F) and body size (G).
UR - http://www.scopus.com/inward/record.url?scp=85153919420&partnerID=8YFLogxK
U2 - 10.1186/s13046-023-02668-3
DO - 10.1186/s13046-023-02668-3
M3 - Comment/debate
C2 - 37101182
AN - SCOPUS:85153919420
SN - 1756-9966
VL - 42
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
IS - 1
M1 - 102
ER -